


RealRate

PHARMACEUTICAL 2021

## Monopar Therapeutics Rank 67 of 402





Monopar Therapeutics



PHARMACEUTICAL 2021



RealRate

Monopar Therapeutics Rank 67 of 402

The relative strengths and weaknesses of Monopar Therapeutics are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Monopar Therapeutics compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Monopar Therapeutics is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 229%, being 182% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	16,800
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,177
Liabilities, Non-Current	0
Other Assets	69
Other Compr. Net Income	3.1
Other Expenses	0
Other Liabilities	0
Other Net Income	82
Other Revenues	122
Property and Equipment	0
Research and Development	4,065
Selling, General and Administrative Expense	2,444

Output Variable	Value in 1000 USD
Assets	16,869
Liabilities	1,177
Expenses	6,509
Revenues	122
Stockholders Equity	15,692
Net Income	-6,305
Comprehensive Net Income	-6,303
Economic Capital Ratio	229%

